Product Evaluation for the Effectiveness of the ClearGuard™ HD End Cap

A trial with no phase registered on ClinicalTrials.gov. The registry status is completed. It enrolled 2912 participants.

Also called NCT02604264

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Not applicable
Enrolled
  • 2,912 participants (enrolled count) (from the registry)
Sponsor
Pursuit Vascular, Inc. (from the registry)
Registry
  • NCT NCT02604264
Other papers using this trial's data
  • Dialysis Catheter-Related Bloodstream Infections: A Cluster-Randomized Trial of the ClearGuard HD Antimicrobial Barrier Cap American journal of kidney diseases : the official journal of the National Kidney Foundation, 2017-02 DOI, PubMed 27839894

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT02604264. Randomized; no masking; primary purpose treatment. Start 2014-12 (actual); primary completion 2015-11 (actual). Results posted on 2017-05-01.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Product Evaluation for the Effectiveness of the ClearGuard™ HD End Cap
Condition
End Stage Renal Disease (ESRD)
Intervention (Device)
ClearGuard HD end cap
Lead sponsor
Pursuit Vascular, Inc. (class: industry)
Collaborator
Fresenius Medical Care North America (class: industry)

Record details

Record id
cardio:ct-nct02604264
Content hash
eeaed44429b674f2edae4215f8bd033b2eb526ce917e8b7391a6c10576ae793f